{"id":"hpv-gsk-580299-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"HPV GSK 580299 is a prophylactic vaccine designed to prevent infection by human papillomavirus types associated with cervical cancer and other HPV-related malignancies. The vaccine contains recombinant HPV L1 capsid proteins or similar immunogenic components that trigger both humoral and cellular immune responses. By priming the immune system before natural HPV exposure, the vaccine prevents viral infection and the subsequent development of HPV-associated cancers.","oneSentence":"This vaccine stimulates the immune system to recognize and attack human papillomavirus (HPV)-infected cells by inducing antibodies and T-cell responses against HPV antigens.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:45:30.365Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of human papillomavirus infection and HPV-associated cervical cancer"},{"name":"Prevention of other HPV-related cancers (anal, oropharyngeal, genital)"}]},"trialDetails":[{"nctId":"NCT00947115","phase":"PHASE3","title":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-09-22","conditions":"Infections, Papillomavirus","enrollment":525},{"nctId":"NCT01031069","phase":"PHASE4","title":"Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10-26","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":873},{"nctId":"NCT01381575","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Two 2-dose Human Papillomavirus (HPV) Vaccine Schedules in 9-14 Year Old Girls","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-06-29","conditions":"Infections, Papillomavirus","enrollment":1447},{"nctId":"NCT00877877","phase":"PHASE3","title":"Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-05-07","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":632},{"nctId":"NCT00637195","phase":"PHASE3","title":"Immunogenicity and Safety of a Commercially Available Vaccine Co-administered With GSK HPV Vaccine (580299)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-11","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":152},{"nctId":"NCT00586339","phase":"PHASE2","title":"Safety and Immunogenicity of GlaxoSmithKline Biologicals' HPV Vaccine 580299 (Cervarix) in HIV Infected Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-17","conditions":"Infections, Papillomavirus","enrollment":150},{"nctId":"NCT00423046","phase":"PHASE3","title":"Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-01-24","conditions":"Infections, Papillomavirus, Papillomavirus Vaccines","enrollment":1106},{"nctId":"NCT00779766","phase":"PHASE3","title":"Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-10-22","conditions":"Infections, Papillomavirus","enrollment":6081},{"nctId":"NCT00492544","phase":"PHASE3","title":"Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-02","conditions":"Infections, Papillomavirus","enrollment":100},{"nctId":"NCT00652938","phase":"PHASE3","title":"Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-04-09","conditions":"Infections, Papillomavirus","enrollment":744},{"nctId":"NCT00541970","phase":"PHASE1","title":"Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-10-17","conditions":"Infections, Papillomavirus","enrollment":961},{"nctId":"NCT00996125","phase":"PHASE3","title":"Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-10-24","conditions":"Infections, Papillomavirus","enrollment":750},{"nctId":"NCT01277042","phase":"PHASE3","title":"Study to Assess Immune Responses and Safety of the GSK-580299 Vaccine in Healthy Women (26 to 45 Years)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2011-02-17","conditions":"Infections, Papillomavirus","enrollment":1212},{"nctId":"NCT00369824","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-09-26","conditions":"Infections, Papillomavirus","enrollment":1330},{"nctId":"NCT00426361","phase":"PHASE3","title":"Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-02-13","conditions":"Infections, Papillomavirus","enrollment":751},{"nctId":"NCT00799825","phase":"PHASE3","title":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Canada or the US","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-01-01","conditions":"Infections, Papillomavirus","enrollment":346},{"nctId":"NCT00546078","phase":"PHASE2","title":"Follow-up Study to Evaluate the Safety and Immunogenicity of a HPV Vaccine (580299) in North America","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-01-14","conditions":"Infections, Papillomavirus","enrollment":116},{"nctId":"NCT00552279","phase":"PHASE3","title":"Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-11-12","conditions":"Infections, Papillomavirus","enrollment":805},{"nctId":"NCT00478621","phase":"PHASE1","title":"Human Papillomavirus Vaccine Safety & Immunogenicity Trial in Healthy Young Adult Women With HPV Vaccine (GSK1674330A)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05-25","conditions":"Infections, Papillomavirus","enrollment":540},{"nctId":"NCT00456807","phase":"PHASE3","title":"Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-04","conditions":"Infections, Papillomavirus","enrollment":100},{"nctId":"NCT00120848","phase":"PHASE2","title":"Follow-up Study of GSK Biologicals' Human Papilloma Virus (HPV) Vaccine to Prevent Cervical Infection in Young Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Infections, Papillomavirus","enrollment":776},{"nctId":"NCT00929526","phase":"PHASE3","title":"Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-06","conditions":"Infections, Papillomavirus","enrollment":752},{"nctId":"NCT00693966","phase":"PHASE2","title":"Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"1999-10","conditions":"Infections, Papillomavirus","enrollment":210},{"nctId":"NCT00693615","phase":"PHASE2","title":"Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2000-10","conditions":"Infections, Papillomavirus","enrollment":60},{"nctId":"NCT00689741","phase":"PHASE2","title":"Efficacy Study of HPV-16/18 Vaccine (GSK 580299) to Prevent HPV-16 and/or -18 Cervical Infection in Young Healthy Women","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2001-01","conditions":"Infections, Papillomavirus","enrollment":1113},{"nctId":"NCT00849381","phase":"PHASE3","title":"Safety Study of GSK Biologicals' Human Papillomavirus Vaccine in 580299/008 Subjects From Brazil, Taiwan or Thailand","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04","conditions":"Infections, Papillomavirus","enrollment":1239},{"nctId":"NCT00316706","phase":"PHASE3","title":"Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-10","conditions":"Cervical Intraepithelial Neoplasia, Papillomavirus Infection","enrollment":1245}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"HPV GSK 580299 vaccine","genericName":"HPV GSK 580299 vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and attack human papillomavirus (HPV)-infected cells by inducing antibodies and T-cell responses against HPV antigens. Used for Prevention of human papillomavirus infection and HPV-associated cervical cancer, Prevention of other HPV-related cancers (anal, oropharyngeal, genital).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}